Microemulsion pharmaceutical composition for treating anterior segment diseases of eyes

By using an oil-in-water microemulsion as a drug storage system for the anterior segment, the problem of difficulty in effectively delivering and maintaining high concentrations of active ingredients in the anterior segment in the prior art is solved, and efficient delivery and long-term maintenance effects are achieved in the treatment of corneal neovascular disease (NV).

CN119730838APending Publication Date: 2025-03-28S I F I SPA
1 Cites 0 Cited by

Patent Information

Application Number
CN202380048113.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-04-29
Filing Date
2023-04-28
Publication Date
2025-03-28

AI Technical Summary

Technical Problem

The prior art is difficult to effectively deliver and maintain high concentrations of active ingredients in the anterior segment, especially in the treatment of corneal neovascular disease (NV).

Method used

Oil-in-water microemulsions are used as the drug storage system for the anterior segment. By including an appropriate amount of oil components, aqueous components and surfactants in the microemulsions, a particle distribution of less than 30 nm is formed, ensuring efficient delivery of active ingredients in the anterior segment and long-term maintenance.

Benefits of technology

Efficient delivery and maintenance of high concentrations of active ingredients in the anterior segment are achieved, especially in the treatment of corneal neovascular disease (NV), which significantly improves the therapeutic effect.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present invention relates to an oil-in-water microemulsion which has been proved to be a suitable drug depot system for the treatment of anterior ocular diseases, wherein the disease is selected from the group consisting of corneal neovascularization disease (NV), ocular melanoma, gel-drop corneal dystrophy (GDLD), secondary corneal amyloidosis-GDLD type, Graves eye disease, Szifen syndrome (SJS), silkworm-erosive corneal ulceration and corneal transplant rejection, more particularly neovascularization disease (NV). The microemulsion according to the present invention is indeed capable of efficiently delivering and maintaining a high concentration of an active ingredient in the anterior segment of the eye after administration.
Need to check novelty before this filing date? Find Prior Art